World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
128
Citations
61285
World Ranking
2711
National Ranking
1514

Claus G. Roehrborn publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Claus G. Roehrborn sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 994 publications — 94th percentile

94% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Claus G. Roehrborn D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Claus G. Roehrborn sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 128 D-Index — 87th percentile

87% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Claus G. Roehrborn is affiliated with The University of Texas Southwestern Medical Center in the United States. Their research primarily focuses on medicine, with a significant emphasis on urology. Over their career, they have contributed extensively to the field of urinary bladder and prostate research.

The scientist's body of work covers various topics within medicine, notably:

  • Urinary Bladder and Prostate Research
  • Prostate Cancer Diagnosis and Treatment
  • Pelvic floor disorders treatments
  • Prostate Cancer Treatment and Research
  • Urological Disorders and Treatments
  • Urologic and reproductive health conditions
  • Sexual function and dysfunction studies

The subfields of study where Claus G. Roehrborn has significant publications include:

  • Urology
  • Pulmonary and Respiratory Medicine
  • Rheumatology
  • Surgery
  • Psychiatry and Mental health

Key recent papers by Claus G. Roehrborn include:

  • Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I-Initial Work-up and Medical Management, 2021, The Journal of Urology
  • Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART II-Surgical Evaluation and Treatment, 2021, The Journal of Urology
  • Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia, 2021, The Journal of Urology
  • Single-cell analysis of mouse and human prostate reveals novel fibroblasts with specialized distribution and microenvironment interactions, 2021, The Journal of Pathology
  • Urethral luminal epithelia are castration-insensitive cells of the proximal prostate, 2020, The Prostate

This researcher has published predominantly in the following venues:

  • The Journal of Urology
  • Urology
  • European Urology Focus
  • International Journal of Radiation Oncology*Biology*Physics
  • Prostate Cancer and Prostatic Diseases

Among frequent collaborators, Claus G. Roehrborn has coauthored multiple works with:

  • Jeffrey Gahan
  • Dean Elterman
  • Ryan Mauck
  • Douglas W. Strand
  • Steven A. Kaplan

Best Publications

  • The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.

    John D. McConnell;Claus G. Roehrborn;Oliver M. Bautista;Gerald L. Andriole

  • Radical prostatectomy versus observation for localized prostate cancer.

    Timothy J. Wilt;Michael K. Brawer;Karen M. Jones;Michael J. Barry

  • The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic Hyperplasia

    J.D. McConnell;R. Bruskewitz;P. Walsh;G. Andriole

  • Update on AUA Guideline on the Management of Benign Prostatic Hyperplasia

    Kevin T. McVary;Claus G. Roehrborn;Andrew L. Avins;Michael J. Barry

  • Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical Prostatectomy

    Andrew J. Stephenson;Peter T. Scardino;Michael W. Kattan;Thomas M. Pisansky

  • Female Stress Urinary Incontinence Clinical Guidelines Panel Summary Report on Surgical Management of Female Stress Urinary Incontinence

    Gary E. Leach;Roger R. Dmochowski;Rodney A. Appell;Jerry G. Blaivas

  • The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT Study

    Claus G. Roehrborn;Paul Siami;Jack Barkin;Ronaldo Damião

  • Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

    Claus G Roehrborn;Peter Boyle;J.Curtis Nickel;Klaus Hoefner

  • Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients

    M.Craig Hall;Sean Womack;Arthur I Sagalowsky;Thomas Carmody

  • Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy

    Andrew J. Stephenson;Shahrokh F. Shariat;Michael J. Zelefsky;Michael W. Kattan

  • Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.

    Steven A. Kaplan;Claus G. Roehrborn;Eric S. Rovner;Martin Carlsson

  • Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials*

    Peter Boyle;Peter Boyle;Peter Boyle;A. Lawrence Gould;A. Lawrence Gould;A. Lawrence Gould;Claus G. Roehrborn;Claus G. Roehrborn;Claus G. Roehrborn

  • Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses

    Yair Lotan;Claus G Roehrborn

  • A Shifted Paradigm for the Further Understanding, Evaluation, and Treatment of Lower Urinary Tract Symptoms in Men: Focus on the Bladder

    Christopher R. Chapple;Claus G. Roehrborn

  • The Relationship between Prostate Inflammation and Lower Urinary Tract Symptoms: Examination of Baseline Data from the REDUCE Trial

    J. Curtis Nickel;Claus G. Roehrborn;Michael P. O'Leary;David G. Bostwick

  • Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.

    Claus G. Roehrborn;Peter Boyle;A.Lawrence Gould;Joanne Waldstreicher

  • Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The prospective european doxazosin and combination therapy (predict) trial

    Roger S Kirby;Claus Roehrborn;Peter Boyle;Georg Bartsch

  • Benign prostatic hyperplasia: Diagnosis and treatment

    J. D. McConnell;M. J. Barry;R. C. Bruskewitz;A. J. Bueschen

  • Tadalafil Relieves Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

    Kevin T. McVary;Claus G. Roehrborn;Jed C. Kaminetsky;Stephen M. Auerbach

  • Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy

    Peter R. Carroll

Frequent Co-Authors

Yair Lotan
Yair Lotan The University of Texas Southwestern Medical Center
Shahrokh F. Shariat
Shahrokh F. Shariat Medical University of Vienna
Kevin T. McVary
Kevin T. McVary Loyola University Medical Center
Pierre I. Karakiewicz
Pierre I. Karakiewicz University of Montreal
Gerald L. Andriole
Gerald L. Andriole Washington University in St. Louis
Jeffrey A. Cadeddu
Jeffrey A. Cadeddu The University of Texas Southwestern Medical Center
Francesco Montorsi
Francesco Montorsi Vita-Salute San Raffaele University
Raymond C. Rosen
Raymond C. Rosen New England Research Institutes
John W. Kusek
John W. Kusek National Institutes of Health
Peter Boyle
Peter Boyle University of Edinburgh

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always mean going to medical school. There are many online degrees and accelerated pathways that can help you advance or pivot your career in healthcare.

For registered nurses, enrolling in rn to bsn programs can be a key step to sharpen skills and improve job prospects—without the need for additional clinical hours. Licensed practical nurses interested in progressing can find flexible, faster options through online lpn programs that open doors to new career opportunities.

If you’re aiming for leadership roles or advanced clinical work, consider a terminal degree in nursing. 1 year dnp program online options offer a streamlined path to a Doctor of Nursing Practice for those wanting to finish quickly. For added convenience, professionals can also explore the easiest online dnp programs that focus on accessible coursework and flexible scheduling.

Online nursing programs are making healthcare careers more accessible—enabling you to balance education with your current life and work.

Best Scientists Citing Claus G. Roehrborn

Trending Scientists

Recently Published Articles